Peptides / Growth hormone axis

Synthetic analog · 83 amino acids · 9,111.6 Da

IGF-1 LR3

Not approvedBanned in sport

IGF-1 LR3 is an engineered, longer form of IGF-1 that binds weakly to its carrier proteins and acts on the IGF-1 receptor. It is not approved and is banned in sport, and its studies are in animals and lab cells. PepBank shows 411 results on IGF-1 LR3 from animal and lab studies. No study in people has reported results yet. Data as of 2026-10-30.

Also known as IGF-I LR3, LR3, LR3-IGF-I, LR3IGF-I, M9L22Y19H9, IGF-1 and 5 more

First 40 of 83 amino acids5 changed amino acids

Evidence level: Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Results in people

0% of 411 results

Results in animals

288

70% of 411 results

Results in lab cells

123

30% of 411 results

From computer models

0% of 411 results

Overview

IGF-1 LR3 at a glance

What it is	Synthetic analog, 83 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2.3)
Studies	127 studies with results. 97 of them gave IGF-1 LR3, with 411 results. 288 in animals123 in lab cells
Clinical trials	None registered
Community use	Muscle growth and recovery in bodybuilding; Tightening up body composition during a strict diet (one 2008 forum report)

The science

What is IGF-1 LR3?

An engineered 83-residue analogue of human IGF-I that binds IGF-binding proteins weakly and activates the IGF-1 receptor. It is a protein, it is not an approved medicine, and no human trials are registered.

Amino acids in one chain

IGF-1 LR3 structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 83 amino acidsFrom the first amino acid to the last

M1FPAM5PLSSL10FVNGP15+RTLCG20A−ELV−D25ALQFV30CG−D+RG35FYFN+K40PTGYG45SSS+R+R50APQTG55IV−D−EC60CF+RSC65−DL+R+RL70−EMYCA75PL+KPA80+KSA

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

IGF-1 LR3 is a synthetic analog of 83 amino acids, with no ring, 3 disulfide bonds, 5 changed amino acids.

Formula

C₄₀₀H₆₁₉N₁₁₁O₁₁₅S₉

Molecular weight

9,111.6 g/mol

CAS number

143045-27-6

Target

Insulin-like growth factor 1 receptor (gene IGF1R): agonistEvidence: primary literature

Development

No company holds an approval or a registered human programme for IGF-1 LR3. First described by Francis GL and colleagues (J Mol Endocrinol 1992, PMID 1378742). It is made and sold as a cell culture reagent and as a research chemical. Highest phase: preclinical.

Identifiers

UNII M9L22Y19H9, PDB 3LRI

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn-Gly-Pro-Arg-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala-OH

See charge, composition and 3D structure on the Scientific page

The evidence

What IGF-1 LR3 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists no trial.

Weight and appetite

50 results · 50 animal

In fetal sheep, LR3 IGF-1 did not clearly change total fetal weight compared with saline. American journal of physiology. Endocrinology and metabolism, 2021

Top results

In fetal sheep, LR3 IGF-1 did not clearly change total fetal weight compared with saline. (American journal of physiology. Endocrinology and metabolism, 2021)
In sheep, food intake was the same with LR3IGF-1 as with rhIGF-1. (Canadian Journal of Animal Science, 1997)
In rats with tumours, the LR3 IGF-I analogue alone did not build carcass protein. (The Biochemical journal, 1994)

Stomach and gut

36 results · 36 animal

In newborn calves, Long-R3-IGF-I had no significant effect on the structure of the small intestine. Journal of animal science, 1998

Top results

In newborn calves, Long-R3-IGF-I had no significant effect on the structure of the small intestine. (Journal of animal science, 1998)
In irradiated rats, an IGF-I analogue did not change how often abnormal gut pressure waves occurred, compared with vehicle. (Journal of gastroenterology and hepatology, 2000)
In rats, the LR3 IGF-I analogue, like IGF-I, increased the weight of gut tissue in a dose-dependent way. (The American journal of physiology, 1994)

Metabolism and nutrition

31 results · 31 animal

In fetal sheep, LR3 IGF-1 lowered amino acid uptake through the umbilical cord compared with saline. American journal of physiology. Endocrinology and metabolism, 2021

Top results

In fetal sheep, LR3 IGF-1 lowered amino acid uptake through the umbilical cord compared with saline. (American journal of physiology. Endocrinology and metabolism, 2021)
In sheep, long-R3-IGF-I infused into the skin increased oxygen use by the skin. (The Journal of endocrinology, 1993)
In rats with tumours, infusing IGF-I or the LR3 IGF-I analogue alone did not build muscle protein. (The Biochemical journal, 1994)

Blood sugar

29 results · 27 animal · 2 lab

In fetal sheep, IGF‑1 LR3 lowered insulin levels in the blood compared with vehicle. American journal of physiology. Endocrinology and metabolism, 2021

Top results

In fetal sheep, IGF‑1 LR3 lowered insulin levels in the blood compared with vehicle. (American journal of physiology. Endocrinology and metabolism, 2021)
In fetal sheep, IGF‑1 LR3 lowered blood glucose compared with vehicle. (American journal of physiology. Endocrinology and metabolism, 2021)
In fetal sheep, LR3 IGF-1 lowered insulin levels compared with saline. (American journal of physiology. Endocrinology and metabolism, 2021)

Sex hormones and fertility

66 results · 26 animal · 40 lab

In immature rats, an IGF-I analogue increased the replication of mural granulosa cells from the ovary. The Journal of endocrinology, 2001

Top results

In immature rats, an IGF-I analogue increased the replication of mural granulosa cells from the ovary. (The Journal of endocrinology, 2001)
In dairy cows, infusing an IGF-I analogue into the udder did not raise milk protein yield. Yield was slightly lower. (Journal of dairy science, 2000)
In mice with impaired mammary development, an IGF-1 analogue brought mammary gland weight and DNA content back to normal. (Development, 2002)

Growth hormone and growth

27 results · 25 animal · 2 lab

In sheep, the body's own IGF-I in the blood was lower than in control sheep by day 7 of LR3IGF-I infusion. The Biochemical journal, 1995

Top results

In sheep, the body's own IGF-I in the blood was lower than in control sheep by day 7 of LR3IGF-I infusion. (The Biochemical journal, 1995)
In cultured ovarian cells, long R3-IGF-I stimulated IGFBP-3 production more strongly than IGF-I. (Endocrinology, 1992)
In sheep, blood IGF-1 fell after 24 hours of LR3IGF-1, while it rose with rhIGF-1. (Canadian Journal of Animal Science, 1997)

All 127 IGF-1 LR3 studies by area Open the Scientific page

Key IGF-1 LR3 studies

Studies in people come first, then studies in animals and in the lab.

Animals
Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect
White et al. 2021 · American journal of physiology. Endocrinology and metabolism · 17 subjects · cited by 9
5 results
Animals
IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus
Stremming et al. 2021 · American journal of physiology. Endocrinology and metabolism · 16 subjects · cited by 24
15 results
Animals
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep
White et al. 2025 · American journal of physiology. Endocrinology and metabolism · 14 subjects · cited by 3
7 results
Animals
Metabolic response of sheep skin to a chronic infusion of a variant of insulin-like growth factor I
Hocking et al. 1995 · The Biochemical journal · 12 subjects · cited by 1
15 results
Animals
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets
White et al. 2023 · Journal of developmental origins of health and disease · 10 subjects · cited by 1
3 results

All 127 IGF-1 LR3 studies

IGF-1 LR3 clinical trials

ClinicalTrials.gov lists no trial of IGF-1 LR3. A trial under another name may exist.

Status and safety

Is IGF-1 LR3 approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.3.

No. Not approved for any use. Preclinical research only. No clinical trial phase found. The FDA, the EMA and the other sources we use show no approval (as of 13 Oct 2026). Banned in sport (WADA S2.3).

Laws and labels change, so check the regulator for the current status.

IGF-1 LR3 side effects and safety

PepBank has 7 safety results from studies of IGF-1 LR3. None of them come from studies in people, so they do not show what happens in people.

Safety results from studies (7)

In dairy cows, the milk cell count rose after an IGF-I analogue was infused into the udder. (Journal of dairy science, 2000)
In mice with cancer cachexia, LR3 IGF-I sped up tumour growth compared with vehicle. (Scientific reports, 2019)
In rats with acute kidney injury, the LR3 IGF-I analogue made kidney filtration fall more than in untreated rats. (The Journal of endocrinology, 1994)
In rats with acute kidney injury, the LR3 IGF-I analogue lowered urine concentration compared with untreated rats. (The Journal of endocrinology, 1994)
In rats with acute kidney injury, the LR3 IGF-I analogue increased sodium loss in urine compared with untreated rats. (The Journal of endocrinology, 1994)
In rats with acute kidney injury, the LR3 IGF-I analogue was linked to more calcium deposits in kidney tubules. (The Journal of endocrinology, 1994)
In lab tests, more oocytes degenerated in bovine follicles treated with LR3 IGF-I than in controls or follicles with normal hrIGF-I doses. (Reproduction, 2007)

See every safety result on the Scientific page

Doses studied (38 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1.17 ± 0.12 µg/kg/h	Animal	sheep	infusion into fetal circulation	1 week	Study in live animals · n = 14	White 2025
5 mg/kg per day	Animal	rat	osmotic mini-pump	Not reported	Study in live animals · n = 7	Fraser 2000
50 microg/[kg BW x d]	Animal	calf	subcutaneous or oral	7 d	Study in live animals	Bühler 1998
44, 111 or 278 micrograms/day	Animal	rat	osmotic minipump	14 days	Study in live animals	Steeb 1994
278 micrograms/day	Animal	rat	osmotic minipump	14 days	Study in live animals	Steeb 1994
50 micrograms/kg body weight/day	Animal	calf	subcutaneous	7 days	Study in live animals	Hammon 1997
1 microgram	Animal	rat	intracerebroventricular	Not reported	Study in live animals	Harel 1992
2.5 mg/kg/day	Animal	rat	Not reported	3 days	Study in live animals	Steeb 1995
44 micrograms/day	Animal	rat	subcutaneous osmotic pump	14 days	Study in live animals	Tomas 1993
278 micrograms/day	Animal	rat	subcutaneous infusion	7 days	Study in live animals	Lemmey 1994
125 micrograms/kg/h	Animal	rat	intravenous	20 min	Study in live animals	Gillespie 1997
120 micrograms/day	Animal	guinea pig	Not reported	7 days	Study in live animals	Conlon 1995
180 micrograms/kg/day	Animal	pig	infusion	4 days	Study in live animals	Dunaiski 1997
20 and 50 micrograms/kg body weight	Animal	pig	bolus injection	Not reported	Study in live animals	Tomas 1997
320 and 400 micrograms/day	Animal	rat	continuous subcutaneous infusion	7 days	Study in live animals	Tomas 1996
400 micrograms/day	Animal	rat	subcutaneous injection	7 days	Study in live animals	Tomas 1996
200 or 500 microgram/day	Animal	rat	osmotic minipump	6-7 days	Study in live animals	Tomas 1994
2, 4 or 8 microg/h	Animal	pig	infusion	8 days	Study in live animals	Dunshea 2002
8 microg/h	Animal	pig	infusion	9 days	Study in live animals	Dunshea 2002
16 microg/h	Animal	pig	infusion	9 days	Study in live animals	Dunshea 2002
50 micrograms/[kg x day], twice daily	Animal	cattle	subcutaneous	7 days	Study in live animals	Hammon 1998
10x10(6) c.p.m.	Animal	rat	intravenous	single bolus	Study in live animals	Bastian 2000
1.5 mg/kg per day	Animal	rat	subcutaneous osmotic pump	7 days	Study in live animals	Martin 1994
1 ng/ml plasma	Animal	lamb	intra-arterial infusion into an intestinal segment	45 min	Study in live animals	Lord 1994
280 ug PLGA-encapsulated	Animal	rat	implanted in hydrogel muscle void filler	28 days	Study in live animals	Clark 2026
28 ug or 280 ug	Animal	rat	implanted in hydrogel muscle void filler	Not reported	Study in live animals	Clark 2026
2.6 microg/kg	Animal	rat	intravenous bolus	single bolus	Study in live animals	Shoubridge 2003
0.1-1.7 nM	Lab	rat	Not reported	Not reported	Study on tissue taken from a body	Fex 1996
20 to 100 ug/l	Lab	sheep	serosal application	within 30 min	Study on tissue taken from a body	Shen 2012
20 ug/l	Lab	sheep	serosal application	Not reported	Study on tissue taken from a body	Shen 2012
100 ng ml-1	Lab	bovine	Not reported	Not reported	Study on cells in a dish · n = 5	Lavranos 1996
2-50 ng/ml	Lab	bovine	Not reported	144 h	Study on cells in a dish	Glister 2001
10 ng/ml	Lab	pig	Not reported	Not reported	Study on cells in a dish	Shores 2000
100 ng/ml	Lab	pig	Not reported	Not reported	Study on cells in a dish	Shores 2000
1 nM	Lab	rat	Not reported	Not reported	Study on cells in a dish	Barnea 1993
12.5 micrograms/l	Lab	bovine	Not reported	Not reported	Study on cells in a dish	Zhao 1993
100 micrograms/l	Lab	bovine	Not reported	Not reported	Study on cells in a dish	Zhao 1993
10 or 100 ng/ml	Lab	bovine	Not reported	Not reported	Study on cells in a dish	Nwachukwu 2023

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

People use IGF-1 LR3 mainly in bodybuilding, for muscle fullness, growth and recovery. Sources report small daily injections of about 20 to 50 mcg in cycles of 4 to 6 weeks, and no human clinical trials exist.

Reported routines and cautions

What people use it for

Muscle growth and recovery in bodybuildingS1S2S4S5
Tightening up body composition during a strict diet (one 2008 forum report)S3

Reported regimens

Regimens that community sources report for IGF-1 LR3. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Muscle growth and recovery (bodybuilding)	subcutaneous or intramuscular injectionS2 says some users inject into recently trained muscle and others inject under the skin.	20 to 50 mcg per dose	once daily (S2: on training days; S1: ideally after the workout)	4 to 6 weeks on, then a break of equal length (S1)	2 sources agree on route, once-daily dosing and 4 to 6 weeks; the upper amount differs (S1 20 to 40 mcg, S2 20 to 50 mcg). S2 carries seller rankings, and S1 cites a seller blog for this row.	S1S2
Higher-dose reports	intramuscular injection (S2); not stated (S4)	50 to 100 mcg per dose	once daily after training (S2); four times a week after training (S4)	3 to 6 weeks	sources differ: S2 gives a daily plan of 4 to 6 weeks, S4 gives four injections a week for 3 weeks, and S6 gives only a wide daily range. S4 is a single user.	S2S4S6
Split doses (old forum thread)	Not statedNo route is stated in the quotes.	20 mcg per dose	twice daily (morning and after training in one report; morning and bedtime in another)	Not stated	single source (two posters in one thread, 2008)	S3
Alternating with MGF (10-day plan)	intramuscular injection	40 to 50 mcg per dose	every other day, alternating with MGF	10 to 20 days per cycle	single source; S2 carries seller rankings	S2

Reported side effects

low blood sugar (hypoglycemia)S2S5 S6
water retention and bloatingS3S4
gut distention at higher doses or longer useS2

Reported benefits (claims, not shown in trials)

muscle pump and fullnessS2S4
faster recovery between sessionsS2S4
modest strength gainsS2S4

Cautions

No human clinical trial of IGF-1 LR3 exists. All community amounts come from self-experiment, not dose-finding studies.S1S2
Hypoglycemia is the risk that sources stress most. Native IGF-1 can lower blood sugar like insulin, and an overdose can lead to unconsciousness or even death. Not all effects of LR3 in humans are known, and they are presumed to be like those of ordinary IGF-1.S5 S6
Sources describe a theoretical concern that raised IGF-1 signalling could speed the growth of existing tumours. No long-term study has looked at cancer in people using IGF-1 LR3.S5 S6
The product is sold as a research chemical or made by compounding pharmacies, without strong quality oversight. In 2019 FDA enforcement reports list two recalls of compounded IGF-1 LR3 injections for lack of sterility assurance.S6 S7
Some users report no gain. One 2008 forum user reports no gain at up to 120 mcg a day.S3

Status notes

IGF-1 LR3 is not approved by the FDA for any use. The approved drug mecasermin (Increlex) is native IGF-1, a different substance.S1 S6
WADA lists 'Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues' in S2.3 of the 2026 Prohibited List, prohibited at all times. The 2027 List has the same line. LR3 is not named, and S6 treats it as covered.S8 S6
Finland classifies IGF-1 and LR3IGF-1 as doping substances in its Criminal Code, according to the Finnish anti-doping information service.S5

Community sources

S1The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (Frontiers in Endocrinology, 2026) (opens in a new tab)pmc.ncbi.nlm.nih.gov
S2IGF-1 LR3: Community Protocols & Anecdotal Reportspeptideprotocolwiki.comcarries seller links, not linked
S3IGF1-LR3 dosing (EliteFitness forum thread, 2008)elitefitness.comcarries seller links, not linked
S4Ran my first IGF-1 LR3 cycle (Iron Magazine forum thread, 2014)ironmagazineforums.comcarries seller links, not linked
S5Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1) (opens in a new tab)dopinglinkki.fi
S6IGF-1 LR3: Insulin-Like Growth Factor Profile (opens in a new tab)peptidejournal.org
S7openFDA drug enforcement reports: IGF-1 LR3 recalls (D-0456-2019, D-0464-2019) (opens in a new tab)api.fda.gov
S8WADA 2026 Prohibited List, S2.3 (opens in a new tab)wada-ama.org

Gaps

No label dose exists because the substance has no approval, so there is no label regimen. No Longecity, Meso-Rx or ThinkSteroids page could be fetched: Longecity and Meso-Rx showed no usable IGF-1 LR3 thread in search, and ThinkSteroids returned a bot-check page. The anabolicsteroidforums thread (2023) was read but not used because its dosing advice (50 to 100 mcg) comes from a seller's board representative. The EliteFitness thread by a 'Peptide Sponsor Rep' was read for mechanism only and not used. S1 draws its dosing row from a seller blog, and S2 lists seller blogs and Reddit as its sources, so the numbers may all trace back to the same seller pages. The Finnish page (S5) says IGF-1 is used 'in standard doses without breaks', which differs from the 4 to 6 week cycles in S1 and S2. Reconstitution and storage details in S2 were not recorded as regimens. The WADA PDF (S8) cannot be quote-checked by the script (PDF); its wording was read as text. Reddit cannot be fetched.

Questions and more

Ask a question about IGF-1 LR3

The answer links to every study it uses.

What does the evidence say about IGF-1 LR3?Is IGF-1 LR3 tested in people?Compare with HGH (somatotropin)Compare with Hexarelin

Sources

Database: PepBank data for IGF-1 LR3 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about IGF-1 LR3

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

IGF-1 LR3

Not approvedBanned in sport

Also known as IGF-I LR3, LR3, LR3-IGF-I, LR3IGF-I, M9L22Y19H9, IGF-1 and 5 more

What it is

Synthetic analog, 83 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2.3)

Studies

127 studies with results. 97 of them gave IGF-1 LR3, with 411 results.
288 in animals123 in lab cells

Clinical trials

None registered

Community use

Muscle growth and recovery in bodybuilding; Tightening up body composition during a strict diet (one 2008 forum report)

Dose as reported

Class

Species

Route

Duration

Design

Source

1.17 ± 0.12 µg/kg/h

Animal

sheep

infusion into fetal circulation

1 week

Study in live animals · n = 14

White 2025

5 mg/kg per day

Animal

rat

osmotic mini-pump

Not reported

Study in live animals · n = 7

Fraser 2000

50 microg/[kg BW x d]

Animal

calf

subcutaneous or oral

7 d

Study in live animals

Bühler 1998

44, 111 or 278 micrograms/day

Animal

rat

osmotic minipump

14 days

Study in live animals

Steeb 1994

278 micrograms/day

Animal

rat

osmotic minipump

14 days

Study in live animals

Steeb 1994

50 micrograms/kg body weight/day

Animal

calf

subcutaneous

7 days

Study in live animals

Hammon 1997

1 microgram

Animal

rat

intracerebroventricular

Not reported

Study in live animals

Harel 1992

2.5 mg/kg/day

Animal

rat

Not reported

3 days

Study in live animals

Steeb 1995

44 micrograms/day

Animal

rat

subcutaneous osmotic pump

14 days

Study in live animals

Tomas 1993

278 micrograms/day

Animal

rat

subcutaneous infusion

7 days

Study in live animals

Lemmey 1994

125 micrograms/kg/h

Animal

rat

intravenous

20 min

Study in live animals

Gillespie 1997

120 micrograms/day

Animal

guinea pig

Not reported

7 days

Study in live animals

Conlon 1995

180 micrograms/kg/day

Animal

pig

infusion

4 days

Study in live animals

Dunaiski 1997

20 and 50 micrograms/kg body weight

Animal

pig

bolus injection

Not reported

Study in live animals

Tomas 1997

320 and 400 micrograms/day

Animal

rat

continuous subcutaneous infusion

7 days

Study in live animals

Tomas 1996

400 micrograms/day

Animal

rat

subcutaneous injection

7 days

Study in live animals

Tomas 1996

200 or 500 microgram/day

Animal

rat

osmotic minipump

6-7 days

Study in live animals

Tomas 1994

2, 4 or 8 microg/h

Animal

pig

infusion

8 days

Study in live animals

Dunshea 2002

8 microg/h

Animal

pig

infusion

9 days

Study in live animals

Dunshea 2002

16 microg/h

Animal

pig

infusion

9 days

Study in live animals

Dunshea 2002

50 micrograms/[kg x day], twice daily

Animal

cattle

subcutaneous

7 days

Study in live animals

Hammon 1998

10x10(6) c.p.m.

Animal

rat

intravenous

single bolus

Study in live animals

Bastian 2000

1.5 mg/kg per day

Animal

rat

subcutaneous osmotic pump

7 days

Study in live animals

Martin 1994

1 ng/ml plasma

Animal

lamb

intra-arterial infusion into an intestinal segment

45 min

Study in live animals

Lord 1994

280 ug PLGA-encapsulated

Animal

rat

implanted in hydrogel muscle void filler

28 days

Study in live animals

Clark 2026

28 ug or 280 ug

Animal

rat

implanted in hydrogel muscle void filler

Not reported

Study in live animals

Clark 2026

2.6 microg/kg

Animal

rat

intravenous bolus

single bolus

Study in live animals

Shoubridge 2003

0.1-1.7 nM

Lab

rat

Not reported

Study on tissue taken from a body

Fex 1996

20 to 100 ug/l

Lab

sheep

serosal application

within 30 min

Study on tissue taken from a body

Shen 2012

20 ug/l

Lab

sheep

serosal application

Not reported

Study on tissue taken from a body

Shen 2012

100 ng ml-1

Lab

bovine

Not reported

Study on cells in a dish · n = 5

Lavranos 1996

2-50 ng/ml

Lab

bovine

Not reported

144 h

Study on cells in a dish

Glister 2001

10 ng/ml

Lab

pig

Not reported

Study on cells in a dish

Shores 2000

100 ng/ml

Lab

pig

Not reported

Study on cells in a dish

Shores 2000

1 nM

Lab

rat

Not reported

Study on cells in a dish

Barnea 1993

12.5 micrograms/l

Lab

bovine

Not reported

Study on cells in a dish

Zhao 1993

100 micrograms/l

Lab

bovine

Not reported

Study on cells in a dish

Zhao 1993

10 or 100 ng/ml

Lab

bovine

Not reported

Study on cells in a dish

Nwachukwu 2023

Context

Route

Amount

How often

How long

Agreement

Sources

Muscle growth and recovery (bodybuilding)

subcutaneous or intramuscular injectionS2 says some users inject into recently trained muscle and others inject under the skin.

20 to 50 mcg per dose

once daily (S2: on training days; S1: ideally after the workout)

4 to 6 weeks on, then a break of equal length (S1)

2 sources agree on route, once-daily dosing and 4 to 6 weeks; the upper amount differs (S1 20 to 40 mcg, S2 20 to 50 mcg). S2 carries seller rankings, and S1 cites a seller blog for this row.

S1S2

Higher-dose reports

intramuscular injection (S2); not stated (S4)

50 to 100 mcg per dose

once daily after training (S2); four times a week after training (S4)

3 to 6 weeks

sources differ: S2 gives a daily plan of 4 to 6 weeks, S4 gives four injections a week for 3 weeks, and S6 gives only a wide daily range. S4 is a single user.

S2S4S6

Split doses (old forum thread)

Not statedNo route is stated in the quotes.

20 mcg per dose

twice daily (morning and after training in one report; morning and bedtime in another)

Not stated

single source (two posters in one thread, 2008)

Alternating with MGF (10-day plan)

intramuscular injection

40 to 50 mcg per dose

every other day, alternating with MGF

10 to 20 days per cycle

single source; S2 carries seller rankings

IGF-1 LR3

IGF-1 LR3 at a glance

What is IGF-1 LR3?

IGF-1 LR3 structure and chemistry

What IGF-1 LR3 studies show

Weight and appetite

Stomach and gut

Metabolism and nutrition

Blood sugar

Sex hormones and fertility

Growth hormone and growth

Key IGF-1 LR3 studies

IGF-1 LR3 clinical trials

Is IGF-1 LR3 approved?

IGF-1 LR3 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about IGF-1 LR3

Related peptides

Sources

IGF-1 LR3

IGF-1 LR3 at a glance

What is IGF-1 LR3?

IGF-1 LR3 structure and chemistry

What IGF-1 LR3 studies show

Weight and appetite

Stomach and gut

Metabolism and nutrition

Blood sugar

Sex hormones and fertility

Growth hormone and growth

Key IGF-1 LR3 studies

IGF-1 LR3 clinical trials

Is IGF-1 LR3 approved?

IGF-1 LR3 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about IGF-1 LR3

Related peptides

Sources